| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 3.901 | 128.386 | 192.688 | 158.077 | 132.263 | 162.818 | 193.254 | 203.237 |
| Total Income - EUR | - | - | 4.055 | 128.544 | 192.920 | 158.608 | 133.238 | 164.926 | 195.929 | 204.196 |
| Total Expenses - EUR | - | - | 5.383 | 110.441 | 177.958 | 156.168 | 148.666 | 183.326 | 196.904 | 173.467 |
| Gross Profit/Loss - EUR | - | - | -1.327 | 18.103 | 14.962 | 2.440 | -15.429 | -18.399 | -974 | 30.730 |
| Net Profit/Loss - EUR | - | - | -1.370 | 16.815 | 13.033 | 1.201 | -16.668 | -20.048 | -2.934 | 25.455 |
| Employees | - | - | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
Check the financial reports for the company - D.d. Drugs Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 0 | 0 | 57.855 | 47.682 | 36.351 | 26.756 | 16.824 | 7.097 |
| Current Assets | - | - | 7.255 | 35.637 | 41.346 | 48.431 | 34.005 | 51.018 | 38.379 | 47.515 |
| Inventories | - | - | 5.171 | 20.888 | 13.996 | 24.983 | 15.877 | 14.342 | 21.520 | 27.073 |
| Receivables | - | - | 0 | 4.577 | 4.646 | 7.937 | 15.864 | 25.659 | 11.431 | 11.890 |
| Cash | - | - | 2.084 | 10.172 | 22.705 | 15.511 | 2.265 | 11.017 | 5.429 | 8.553 |
| Shareholders Funds | - | - | -1.326 | 15.513 | 28.246 | 28.912 | 11.603 | -8.409 | -11.317 | 12.961 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 8.582 | 20.124 | 71.046 | 70.406 | 58.753 | 86.183 | 66.521 | 41.651 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - D.d. Drugs Srl